Additionally, the study found that weight gain after stopping was strongly associated with reinitiation, suggesting that many patients may need long-term therapy to maintain weight loss. The researchers concluded more studies are needed to explore how long-term health outcomes are tied to GLP-1 discontinuation and to assess how interventions financial barriers to the drugs and mitigate adverse events
October 4, 2024: Sharp Rise in Lawsuits Against Eli Lilly and Other GLP-1 Manufacturers September 24, 2024: Alabama Woman Files Mounjaro Lawsuit Against Eli Lilly for Severe Gastrointestinal Injuries September 10, 2024: Mounjaro Drugmaker to Sell Tirzepatide D2C Through Its Online Pharmacy Eli Lilly, the manufacturer of Mounjaro, recently announced plans to begin selling low doses of tirzepatide, the active ingredient in Mounjaro and Zepbound, directly to consumers
Lose up to 20% of your body weight * and improve your overall health with Wegovy ** through Hims Lower your blood pressure Lower your cholesterol Improve your blood sugar Lower the risk of major cardiovascular events Along with a reduced calorie diet and increased exercise
exposure to freezing temperatures irreversibly damages the peptide structure, rendering the medication ineffective and unsafe for use
